While he was in conversations to add a new shareholder from the cryptocurrency business, The local Bioceres group has just given its operations to one of its controlled companies.
The holding company that controls, for example, Rizobacter, agricultural microbiology laboratory that is its bad ship in business, closed a complex transaction with Moolec Science, Considered as a new local unicorn and where the Bioceres Group itself has more than 40% of its capital, and has a market value greater than US $1 billion.
Bioceres: The largest local biotechnology company yields operations
The company is dedicated to the production of animal proteins by using different crops and trades in the Nasdaq under the Mec Ticker, transforming into the second company of the Bioceres group to do so, in addition to Crops Bioceres (Biox).
Moolec uses genetically modified plants to transform them into animal protein and so far has created two products: chymosine, which is a protein used in cheese production, and gamma-linoleic acid nutrition oil that produces animal proteins and that has global operations in North America and South America and customers in more than 15 countries.
According to the Specialized Investing.com portal, after the operation, Moolec Science SA has signed this agreement with Group Limited bioceres and other entities. According to researchpro data, Bioceres currently operates with a market capitalization of US $259.62 million and maintains gross benefit margins of 41.55%.
The transaction, totally in actions, will result in Moolec becomes the parent company of an expanded corporate structure.
The agreement contemplates that Group Bioceres, Nutrecon LLC and Gentle Technologies Corp transfer their participations to Moolec, which, In return, it will issue up to 87 million new shares and 5 million warrants for the shareholders of the contributory entities.
Specifically, and in accordance with the terms and conditions of the agreement signed last April 17, there will be a transfer of shares in Group bioceres; Nutrecon LLC and Gentle Technologies Corp, which will result in an expanded corporate structure with Moolec as a parent company.
The operation contemplates a millionaire exchange
In return, this holding will issue a combination of up to 87 million shares and 5 million warrants to the shareholders of these companies.
After the closure of this business combination, Moolec will be positioned in the agricultural value chain, with a new value proposal that will focus on modifying or improving seeds and microbes to have a positive impact on the way we use land and water resources, while preserving and/or improving human health.
In addition, the companies and brands that will be controlled or co-controlled by Moolec, After this agreement they will administer a portfolio of more than 800 patents and 550 product recordswhich translates into more than US $ 500 million in goods and services sold to customers in more than 50 different countries.
This business scheme was unanimously approved by the Board of Directors of all the companies involved in the operation and is expected to close during the second quarter of this 2025 will finish specifying.
As part of the DEAL, the Bioceres Group Shareholders renounce their participation in that conglomerate and will receive up to 80,590,280 Moolec shares.
Similarly, Nutrecon 100% shareholders and 50% of Gentle Tech will renounce these holdings and receive 6,475,000 Moolec shares and 5,000,000 Warrants of Moolec at an exercise price of US $ S2 per Warrant, subject to adjustments based on the results of the inverse division process of shares.
Sale and issuance of shares: a “bold” operation
Bioceres sources consulted by iprofesional They said to ignore the operationbut they assured that it is not about the sale of the local conglomerate.
Meanwhile, There were no answers from Moolec executives to an email sent by this means To obtain more details about this complex shareholding operation.
However, through a statement prepared by the authorities of Moolec, Federico Trucco, member of the Bioceres Group Board of Directors and Executive Director of Bioceres Crop Solutions Corp, referred to the transaction.
“The need to accelerate agricultural innovation to address current and future challenges, such as improving the profitability of agricultural farms and reducing environmental impact, is increasingly evident,” he said.
For the Executive, “molecular agriculture, as evidenced by Moolec Science, offers a convincing solution to the challenge of balance productivity and sustainability.”
In the same way, he argued that “Moolec’s recent transaction represents the necessary bold action class to boost a radical change in agriculture. The integration of technologies and abilities, together with a holistic perspective of agricultural evolution, is essential to go beyond incremental improvements. The scale and visibility, both key aspects of this transaction, are crucial to achieve this goal. “
In this sense, Juan Sartori, founder and president of Union Group, added that “it is not only a strategic business alignment, but also The creation of a new type of company for the 21st century. When combining science, scale and sustainability, Moolec is positioned to lead a global transformation in food, material and energy production. I am proud to support this vision and the exceptional teams that make it come true. “
The new Moolec value proposal will focus on the modification or improvement of seeds and microbes to positively influence the way we use terrestrial and water resources, while preserving and/or improving human health.
The Bioceres Business Plan
Meanwhile, José López Lecube, financial director and director of Moolec, explained that the transaction “marks a new stage for Moolec, positioning it for growth within a broader organization that facilitates synergies to multiple levels. Being part of a larger organization will allow cost efficiencies and a significant increase in income, as well as the diversification of the product portfolio. Will also expand our investor base, providing the company with new interest groups that support the new and more diversified Moolec business. “
As part of the new business plan, Moolec will continue to develop its star products of molecular agriculture, such as Piggy Sooy and Glaso, while integrating Mycofood under the eternal brand of Nutrecon.
Meanwhile, through the Bioceres Group, it will offer UPSTREAM technologies for regenerative agriculture, including biological supplies and weather resilient seeds such as Rizobacter, Profarm and HB4 feature.
The company will also expand its scope towards emerging technologies for the transformation of grains and biomass, especially in the field of biomaterials, as well as towards new concepts in agricultural teams that integrate the science of materials, electrical mobility and autonomy. Gentle Tech and Bioceres Group subsidiaries are exploring these emerging opportunities.
The business combination is expected to generate significant cost synergies and an integrated management structure, which will be presented at the closure of the business combination or before.
Until now, Bioceres was considered a comprehensive provider of solutions for agricultural productivity, including patented technologies for microbial agricultural supplies and supplies, as well as nutrition solutions and protection of last generation crops.
The company developed HB4 technology, which gives tolerance to climatic changes in soybeans and wheat, allowing them to tolerate drought and salinity of the soil.
Besides, It has and license more than 570 products with approximately 750 patents and patent requests in the United States, Canada, Brazil, Argentina and other countries.
In the case of Agrality® it is a global supplier of agricultural services that serves agroindustrial companies around the world.
Its comprehensive service offer covers seed manufacturing, R&D, field tests and regulatory capabilities, guaranteeing comprehensive solutions.
AGRALITY key assets include advanced seed production facilities, which allow the development and production of high quality seeds.
Biotechnology giant
In the case of bioceres, it is currently a biotechnology company focused on the creation of solutions for agricultural productivity and sustainability.
It was created in 2001, by a group of 23 members who put from their pocket US $ S600 each to create a new business model in this sector.
At present, there are 308 partners of this group who, after disembarking in the New York Stock Hugo Sigman, with 5% of the shares, is the main individual shareholder.
Its main asset is the development of transgenic modifications that help crops to resist extreme climatic conditions, allowing to reduce losses and optimize yields in adverse contexts. The company is also characterized by investing constantly in research and development and has more than 700 registered patents.
One of its most important milestones is HB4 technology, a gene that confers drought tolerance in crops such as wheat and soy. This development was obtained and patented in conjunction with the scientist Raquel Chan del CONICET and the National University of the Coast.
Besides, It produces a vital input for cheese coagulation – the chymosine – from transgenic caramous. And in 2020 he announced his entry in Moolec, a British company that seeks to incorporate, transgenesis, animal proteins in plant crops. On the other hand, he expanded his action towards biomaterials, with dry construction panels from wheat storm, among many other initiatives.
In turn, it has a diversified portfolio of assets, which includes Crop Solutions bioceres, its international arm dedicated to integrated solutions for crops; Rizobacter, one of the leading agricultural microbiology companies in the world that has its basis of operations in Argentina; and Indear (Institute of Agrobiotechnology of Rosario), its research and development platform.
In 2019, the company took a bold step by beginning to quote its actions in Nasdaq under the Biox symbol, which allowed it to attract international investments and expand its presence in the global market.
Regarding its billing, Bioceres reported significant growth in its income during fiscal year 2024. According to financial results, the company reached a turnover of 464.8 million dollars, which represents an increase of 11% compared to the previous year.
This growth is mainly attributed to the increase in sales of products such as HB4, adjuvants and bioestimulants. In turn, in the fourth quarter of 2024, Bioceres registered income of 124 million dollars, 18% more than the previous year.
In 2022, the American company of the same sector Marrone Bio Innovations (MBI) acquired through a process of exchange of shares of both companies, quotes in the Nasdaq in the framework of a DEAL that was carried out based on a Valuation of Marrone Bio Innovations of U $ S240 million.
